Related Experiment Video

Updated: Aug 14, 2026

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi

H Miyake1, A Tolcher, M E Gleave

  • 1The Prostate Centre, Vancouver General Hospital, British Columbia, Canada.

Cancer Research
|August 27, 1999
PubMed

Insights

Antisense Bcl-2 oligodeoxynucleotide (ODN) therapy effectively reduced Bcl-2 expression in prostate cancer cells. This approach delayed androgen-independent recurrence in a mouse model, showing potential for adjuvant prostate cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Androgen-independence is a major challenge in advanced prostate cancer treatment.
  • Bcl-2 is upregulated in prostate cancer cells during progression to androgen-independence.
  • Targeting Bcl-2 offers a potential therapeutic strategy.

Purpose of the Study:

  • To evaluate the efficacy of antisense Bcl-2 oligodeoxynucleotide (ODN) therapy.
  • To determine if adjuvant antisense Bcl-2 ODN therapy can delay androgen-independent recurrence after castration.
  • To assess the specificity of antisense Bcl-2 ODN in prostate cancer models.

Main Methods:

  • In vitro treatment of Shionogi tumor cells with antisense Bcl-2 ODN.
  • Systemic administration of antisense Bcl-2 ODN in mice with androgen-dependent Shionogi tumors postcastration.
  • Monitoring tumor regression and emergence of androgen-independent recurrent tumors.
  • Assessing Bcl-2 expression in tumor tissues and normal mouse organs.

Main Results:

  • Antisense Bcl-2 ODN inhibited Bcl-2 expression in a dose-dependent and sequence-specific manner in vitro.
  • Systemic antisense Bcl-2 ODN treatment led to more rapid tumor regression.
  • A significant delay in the emergence of androgen-independent recurrent tumors was observed.
  • Antisense Bcl-2 ODN reduced Bcl-2 expression in tumors but not in normal organs.

Conclusions:

  • Antisense Bcl-2 ODN therapy is effective in reducing Bcl-2 expression in prostate cancer cells.
  • Adjuvant antisense Bcl-2 ODN therapy can delay androgen-independent recurrence in prostate cancer.
  • This therapy shows potential for use alongside androgen ablation in prostate cancer treatment.

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...